Search Login Register

lanreotide (Somatuline) Summary

278 relevant articles (60 outcomes, 60 trials/studies) found for this Drug

Description: somatostatin analogue that suppresses GH/IGF-I hypersecretion in acromegaly patients and used to manage neuroendocrine tumours; do not confuse with BIM 23014 C; amino acid sequence given in first source

Also Known As: Somatuline; 188Re-lanreotide; 2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide; BIM 23014; BIM 23014C Show All >>

Key Diseases for which lanreotide is Relevant

  1. Acromegaly : 32 outcomes 23 studies in 98 results
  2. Neoplasms (Cancer) : 9 outcomes 8 studies in 66 results
  3. Carcinoid Tumor (Carcinoid) : 7 outcomes 5 studies in 27 results
  4. Syndrome : 4 outcomes 1 study in 11 results
  5. Pituitary Neoplasms (Pituitary Adenoma) : 3 outcomes 5 studies in 17 results
Show All >>

Drugs Related to lanreotide

  1. Octreotide (Sandostatin)
  2. Somatostatin (Somatotropin Release-Inhibiting Factor)
  3. Insulin-Like Growth Factor I (IGF-1)
  4. Somatostatin Receptors (Somatostatin Receptor)
  5. lanreotide (Somatuline)
  6. vapreotide
  7. Hormones
  8. Glucose (Dextrose)
  9. Interferon-alpha (Interferon Alfa)
  10. pegvisomant
Show All >>

Therapies Related to lanreotide

  1. Drug Therapy (Chemotherapy)
  2. Castration
  3. Pancreatectomy
  4. Aftercare (After-Treatment)
  5. Homologous Transplantation (Allograft)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2008 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.